

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

<p>1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?</p>
<p>Stakeholders highlighted that people from lower socio-economic backgrounds may be less able to make changes to diet, exercise or access to regular support and equity of access to these interventions should be considered. People from lower socio-economic groups as well as some ethnic minority groups are more likely to develop kidney disease (an increased risk for people with obesity) and progress faster to kidney failure. In addition, they face longer waits for transplantation.</p> <p>The scope includes provision that, if evidence allows, consideration may be given to subgroups based on specified characteristics, including age.</p>
<p>2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?</p>
<p>Issues related to differences in prevalence or incidence of a disease cannot typically be addressed in a technology appraisal.</p> <p>However the committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population. If relevant, the committee may also consider any impact of the condition or treatment on health inequalities.</p> <p>If consideration is given to subgroups, including those based on age, the committee will consider any equalities implications in its deliberations.</p>

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The scope specifies that any subgroup considerations will take into account equalities implications.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

Approved by Associate Director (name): Ian Watson

Date: 12 March 2026